Organisation paid for research Program year 2021 Source: CMS Open Payments

Worldwide Clinical Trials Early Pha

Neither a doctor nor a teaching hospital

Research payments

$3,158,961

17 payments

Through program year 2021, Worldwide Clinical Trials Early Pha is reported as receiving $3,158,961 in research payments, across 17 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2021	Research	$1,539,821	8
2020	Research	$1,619,140	9

Breakdown

Who paid Research payments · program years 2020–2021

Hikma Pharmaceuticals USA $3,158,961 17 payments

Studies the money was for Research payments · program years 2020–2021

Comparative Five Groups, Randomized, Single Dose, Three-Treatment, Open Label Study to Evaluate the Dose Proportionality During Dose Escalation of 3.5 mg, 7 mg and 10.5 mg Epinephrine Nasal Spray and Using 0.3 mg EpiPen and 0.5 mg Adrenalin IM Injections as Positive Controls in Healthy Adults Under Fasting Conditions $870,133 1 payment
A Pivotal, Single-Dose, Open-Label, Randomized, Two-Sequence, Full Replicate Bioavailability Study of Epinephrine Nasal Spray 7 mg and Adrenalin 0.5 mg (Epinephrine Intramuscular Injection) with an Add-On Comparator Arm of Epinephrine Injection, 0.3 mg in Healthy Adults $558,529 1 payment
Phase 1, Open-Label, Randomized, Three-Way Crossover, Comparative Bioavailability Study of Epinephrine Nasal Spray and Epinephrine Intramuscular Injection (0.5 mg Adrenalin) and Epinephrine Injection (0.3 mg) in Healthy Adults with Seasonal Allergies $361,660 1 payment
A Single-Dose, Four-Period, Two-Treatment, Full Replicate Bioequivalence Study of Mercaptopurine 20 mg/mL suspension compared to PURIXAN 20 mg/mL suspension $311,813 1 payment
Phase 1, Open-Label, Randomized, Three-Way Crossover, Comparative Bioavailability Study of Epinephrine Nasal Spray and Epinephrine Intramuscular Injection (0.5 mg Adrenalin) and Epinephrine Injection (0.3 mg) in Healthy Adults with Seasonal Allergies $287,207 1 payment
Phase 1, Open-Label, Randomized, Three-Way Crossover, Comparative Bioavailability Study of Epinephrine Nasal Spray and Epinephrine Intramuscular Injection (0.5 mg Adrenalin) and Epinephrine Injection (0.3 mg) in Healthy Adults with Seasonal Allergies $201,500 1 payment
Comparative Five Groups, Randomized, Single Dose, Three-Treatment, Open Label Study to Evaluate the Dose Proportionality During Dose Escalation of 3.5 mg, 7 mg and 10.5 mg Epinephrine Nasal Spray and Using 0.3 mg EpiPen and 0.5 mg Adrenalin IM Injections as Positive Controls in Healthy Adults Under Fasting Conditions $168,764 1 payment
A Phase 1, Single-Dose, Open-Label, Randomized, Crossover, Pharmacokinetic Study of Epinephrine Nasal Spray and Epinephrine Intramuscular Injection (0.3 mg EpiPen and 0.5 mg Adrenalin) in Healthy Adults $145,587 1 payment
Comparative Five Groups, Randomized, Single Dose, Three-Treatment, Open Label Study to Evaluate the Dose Proportionality During Dose Escalation of 3.5 mg, 7 mg and 10.5 mg Epinephrine Nasal Spray and Using 0.3 mg EpiPen and 0.5 mg Adrenalin IM Injections as Positive Controls in Healthy Adults Under Fasting Conditions $95,000 1 payment
Phase 1, Open-Label, Randomized, Three-Way Crossover, Comparative Bioavailability Study of Epinephrine Nasal Spray and Epinephrine Intramuscular Injection (0.5 mg Adrenalin) and Epinephrine Injection (0.3 mg) in Healthy Adults with Seasonal Allergies $91,506 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.